'We want to follow the science here. We don't to get ahead of it,' Gilead Sciences CEO Daniel O'Day told CNBC on Monday.
"If one could do it without an IV, right to the site of where you get this replication of the virus in the lungs, we're also hopeful that you might be able to treat outside the hospital and prevent patients from ever going to the hospital," said O'Day, who became Gilead CEO inAs for the regulatory approval of these potential uses, O'Day said giving people remdesivir through an IV in an outpatient setting such as a nursing home is "probably a shorter timeline.
"The inhaled version, remember, we're moving at light speed in the industry. In fact, from when this virus first showed its head in January, in three months time, we had the first of our gold standard trials," he said. "With a new formulation of a medicine, it does take a little bit longer. So we're in the early stages of testing for [inhaled use]."
Gilead will try to accelerate emergency approvals if possible, he added, but suggested it is likely a 2021 event for more data being available on the efficacy of remdesivir when taken in inhaled form. "Depending on the results we see over the coming months, with this early stage testing, we may be moving this into later-stage trials toward the end of this year, early next year," he said. "We'll just have to see. We want to follow the science here. We don't to get ahead of it."
There are no FDA-approved drugs to treat the coronavirus. In addition to searching for treatments to lessen the severity of the illness, companies and governments around the world also areMore than 29 million people have been infected by the coronavirus worldwide and at least 924,814 people have died,
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead Sciences to buy Immunomedics in over $20 billion dealThe two companies were initially discussing a future partnership before shifting to a takeover negotiation, The Wall Street Journal reported.
Read more »
Gilead to buy cancer drugmaker Immunomedics in $21 billion deal
Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Read more »
WSJ News Exclusive | Gilead Nears Deal to Buy Immunomedics for More Than $20 BillionGilead Sciences is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion, according to people familiar with the matter.
Read more »
Harshmallow: Virus prompts pause for Peeps holiday treatsPeeps treats are going on hiatus for several months — another consequence of the coronavirus pandemic.
Read more »